Opus Genetics, Inc. (IRD) Company Annual Revenue

Opus Genetics Inc (IRD) automates the development of drugs for rare eye pathologies via robotic platforms. The company aims to prevent blindness by utilizing AAV vectors for the delivery of healthy genes. The company's gross sales volume trend shows that the current mark is 0.01. The startup is currently focusing on primary clinical trials of its portfolio before attracting major international partners.

Opus Genetics (IRD): Company Revenue from 10/25/2024 to 11/13/2026

Comprehensive metric breakdowns and analytics for Opus Genetics, Inc. (IRD)

- market price and analyst price targets:

Market Price Opus Bio|IRD - Price Target Chart

- market capitalization details:

Market Valuation Opus Genetics Inc|IRD - Real Price to Acquire Entire Company

- business book valuation details:

Book Value per Share Opus Genetics|IRD - Company Book Value|Market Capitalization to Book Value opusgtx.com|IRD - Cumulative Company Assets

- debt obligations and liquidity statistics:

- net income and valuation ratios data:

IRD - Net Income|Future Net Profit Opus Genetics Inc|IRD - P/E Multiple|Market Cap to Projected Earnings Opus Bio|IRD - PEG Multiple|Enterprise Value to EBITDA Ratio Opus Genetics Inc|IRD - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Opus Genetics|IRD - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months opusgtx.com|IRD - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Opus Genetics Inc

- sales volume and revenue indicators:

IRD - Company Revenue|Company Revenue Forecast Opus Bio|IRD - P/S Multiple|Forward Price-to-Revenue Multiple Opus Genetics Inc

Summary company analysis:IRD (opusgtx.com)

This indicator captures actual daily cash inflows, excluding accounting adjustments to assess real demand. At Opus Genetics Inc (IRD), such liquidity is critically dependent on external financing to offset colossal R&D expenditures for rare eye disease therapies. Analyzing the company's sales metrics allows for the timely detection of operational capital deficits. The stability of this line confirms the business's financial resilience in the face of clinical trial risks.

Analysis of competing companies